Mirian Domenech

Dr. Mirian Domenech

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
MDMirian Domenech
Mirian Domenech
ESElisa Sevillano
Elisa Sevillano
EGErnesto García
Ernesto García
MMMiriam Moscoso
Miriam Moscoso
JYJose Yuste
Jose Yuste
Streptococcus pneumoniae is a frequent member of the microbiota of the human nasopharynx. Colonization of the nasopharyngeal tract is a first and necessary step in the infectious process and often involves the formation of sessile microbial communities by this human pathogen. The ability to grow and persist as biofilms is an advantage for many microorganisms, because biofilm-grown bacteria show reduced susceptibility to antimicrobial agents and hinder recognition by the immune system. The extent of host protection against biofilm-related pneumococcal disease has not been determined yet. Using pneumococcal strains growing as planktonic cultures or as biofilms, we have investigated the recognition of S. pneumoniae by the complement system and its interactions with human neutrophils. Deposition of C3b, the key complement component, was impaired on S. pneumoniae biofilms. In addition, binding of C-reactive protein and the complement component C1q to the pneumococcal surface was reduced in biofilm bacteria, demonstrating that pneumococcal biofilms avoid the activation of the classical complement pathway. In addition, recruitment of factor H, the downregulator of the alternative pathway, was enhanced by S. pneumoniae growing as biofilms. Our results also show that biofilm formation diverts the alternative complement pathway activation by a PspC-mediated mechanism. Furthermore, phagocytosis of pneumococcal biofilms was also impaired. The present study confirms that biofilm formation in S. pneumoniae is an efficient means of evading both the classical and the PspC-dependent alternative complement pathways the host immune system.

1 September 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MDMirian Domenech
Mirian Domenech
EGErnesto García
Ernesto García
MMMiriam Moscoso
Miriam Moscoso
Host- and phage-coded cell wall hydrolases have been used to fightStreptococcus pneumoniaegrowing as planktonic cellsin vitroas well as in animal models. Until now, however, the usefulness of these enzymes in biofilm-grown pneumococci has gone untested. The antipneumococcal activity of different cell wall hydrolases produced byS. pneumoniaeand a number of its phages was examined in anin vitrobiofilm model. The major pneumococcal autolysin LytA, anN-acetylmuramoyl-l-alanine amidase, showed the greatest efficiency in disintegratingS. pneumoniaebiofilms. The phage-encoded lysozymes Cpl-1 and Cpl-7 were also very efficient. Biofilms formed by the close pneumococcal relativesStreptococcus pseudopneumoniaeandStreptococcus oraliswere also destroyed by the phage endolysins but not by theS. pneumoniaeautolysin LytA. A cooperative effect of LytA and Cpl-1 in the disintegration ofS. pneumoniaebiofilms was recorded.

9 September 2011 in Microbial Biotechnology
Verified
Journal Article
Open access
PDF file
MDMirian Domenech
Mirian Domenech
EGErnesto García
Ernesto García
MMMiriam Moscoso
Miriam Moscoso
Summary: Biofilm‐grown bacteria are refractory to antimicrobial agents and show an increased capacity to evade the host immune system. In recent years, studies have begun on biofilm formation by Streptococcus pneumoniae , an important human pathogen, using a variety of in vitro model systems. The bacterial cells in these biofilms are held together by an extracellular matrix composed of DNA, proteins and, possibly, polysaccharide(s). Although neither the precise nature of these proteins nor the composition of the putative polysaccharide(s) is clear, it is known that choline‐binding proteins are required for successful biofilm formation. Further, many genes appear to be involved, although the role of each appears to vary when biofilms are produced in batch or continuous culture. Prophylactic and therapeutic measures need to be developed to fight S. pneumoniae biofilm formation. However, much care needs to be taken when choosing strains for such studies because different S. pneumoniae isolates can show remarkable genomic differences. Multispecies and in vivo biofilm models must also be developed to provide a more complete understanding of biofilm formation and maintenance.

2 April 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
RTRaquel Tarancón
Raquel Tarancón
Jorge Dominguez‐AndresJorge Dominguez‐Andres
Jorge Dominguez‐Andres
SUSantiago Uranga
Santiago Uranga
AFAnaísa V. Ferreira
Anaísa V. Ferreira
LGLaszlo A. Groh
Laszlo A. Groh
MNMihai G. Netea
Mihai G. Netea
Among infectious diseases, tuberculosis is the leading cause of death worldwide, and represents a serious threat, especially in developing countries. The protective effects of Bacillus Calmette-Guerin (BCG), the current vaccine against tuberculosis, have been related not only to specific induction of T-cell immunity, but also with the long-term epigenetic and metabolic reprogramming of the cells from the innate immune system through a process termed trained immunity. Here we show that MTBVAC, a live attenuated strain of Mycobacterium tuberculosis, safe and immunogenic against tuberculosis antigens in adults and newborns, is also able to generate trained immunity through the induction of glycolysis and glutaminolysis and the accumulation of histone methylation marks at the promoters of proinflammatory genes, facilitating an enhanced response after secondary challenge with non-related bacterial stimuli. Importantly, these findings in human primary myeloid cells are complemented by a strong MTBVAC-induced heterologous protection against a lethal challenge with Streptococcus pneumoniae in an experimental murine model of pneumonia. Mycobacterium tuberculosis has been causing infections in our species and our ancestors for at least thousands of years. Still today, the numbers of people affected by tuberculosis are alarming with more than 1,4 million deaths per year, representing the first cause of death by infectious disease worldwide. Despite immense research efforts, Bacille Calmette-Guerin (BCG), a vaccine based on a live attenuated form of Mycobacterium bovis that was developed one century ago, remains the only licensed vaccine against tuberculosis. Several independent works have shown that BCG induces protection not only against tuberculosis, but also against other infections through the induction of epigenetic and metabolic effects in the cells of the innate immune system, what has been termed trained immunity. Here we describe how MTBVAC, a new vaccine against tuberculosis based on a genetically modified form of the human pathogen Mycobacterium tuberculosis, that has shown similar safety profiles and improved protection than BCG in preclinical studies, is able to induce trained immunity in human cells and grant protection against a heterologous model of pneumococcal infection in mice. These results underline the potential of MTBVAC as a candidate for universal vaccination against tuberculosis or treatment against bladder cancer, representing a potential alternative to the current BCG vaccines.

24 September 2021 in Science Immunology
Verified
Journal Article
Closed access
EMElena Mata
Elena Mata
RTRaquel Tarancon
Raquel Tarancon
CGClaudia Guerrero
Claudia Guerrero
EMEduardo Moreo
Eduardo Moreo
FMFlavie Moreau
Flavie Moreau
NANacho Aguilo
Nacho Aguilo
Pulmonary BCG administration induces protection against tuberculosis infection via lung macrophage activation.

3 August 2022 in The Lancet Microbe
Verified
Journal Article
Open access
JSJulio Sempere
Julio Sempere
MLMirella Llamosí
Mirella Llamosí
BRBeatriz López Ruiz
Beatriz López Ruiz
IRIdoia del Río
Idoia del Río
CPCovadonga Pérez-García
Covadonga Pérez-García
JYJose Yuste
Jose Yuste
Epidemiological studies are necessary to explore the effect of current pneumococcal conjugate vaccines (PCVs) against antibiotic resistance, including the rise of non-vaccine serotypes that are resistant to antibiotics. Hence, epidemiological changes in the antimicrobial pattern of Streptococcus pneumoniae before and during the first year of the COVID-19 pandemic were studied. In this national surveillance study, we characterised the antimicrobial susceptibility to a panel of antibiotics in 3017 pneumococcal clinical isolates with reduced susceptibility to penicillin during 2004–20 in Spain. This study covered the early and late PCV7 periods; the early, middle, and late PCV13 periods; and the first year of the COVID-19 pandemic, to evaluate the contribution of PCVs and the pandemic to the emergence of non-vaccine serotypes associated with antibiotic resistance. Serotypes included in PCV7 and PCV13 showed a decline after the introduction of PCVs in Spain. However, an increase in non-PCV13 serotypes (mainly 11A, 24F, and 23B) that were not susceptible to penicillin promptly appeared. A rise in the proportion of pneumococcal strains with reduced susceptibility to β-lactams and erythromycin was observed in 2020, coinciding with the emergence of SARS-CoV-2. Cefditoren was the β-lactam with the lowest minimum inhibitory concentration (MIC)50 or MIC90 values, and had the highest proportion of susceptible strains throughout 2004–20. The increase in non-PCV13 serotypes associated with antibiotic resistance is concerning, especially the increase of penicillin resistance linked to serotypes 11A and 24F. The future use of PCVs with an increasingly broad spectrum (such as PCV20, which includes serotype 11A) could reduce the impact of antibiotic resistance for non-PCV13 serotypes. The use of antibiotics to prevent co-infections in patients with COVID-19 might have affected the increased proportion of pneumococcal-resistant strains. Cefotaxime as a parenteral option, and cefditoren as an oral choice, were the antibiotics with the highest activity against non-PCV20 serotypes. The Spanish Ministry of Science and Innovation and Meiji-Pharma Spain. For the Spanish translation of the abstract see Supplementary Materials section.